NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Price, News & Analysis $3.02 -0.19 (-5.92%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$3.07 +0.05 (+1.66%) As of 03/28/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aquestive Therapeutics Stock (NASDAQ:AQST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aquestive Therapeutics alerts:Sign Up Key Stats Today's Range$2.98▼$3.2050-Day Range$2.54▼$3.4752-Week Range$2.24▼$5.80Volume1.13 million shsAverage Volume1.62 million shsMarket Capitalization$298.59 millionP/E RatioN/ADividend YieldN/APrice Target$10.57Consensus RatingBuy Company OverviewAquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Read More… Remove Ads Aquestive Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreAQST MarketRank™: Aquestive Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 806th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Aquestive Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.46) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -6.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -6.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Aquestive Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.18% of the float of Aquestive Therapeutics has been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Aquestive Therapeutics has recently increased by 2.51%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.18% of the float of Aquestive Therapeutics has been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Aquestive Therapeutics has recently increased by 2.51%, indicating that investor sentiment is decreasing. News and Social Media3.5 / 5News Sentiment1.38 News SentimentAquestive Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aquestive Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for AQST on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.MarketBeat Follows7 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.85% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.45% of the stock of Aquestive Therapeutics is held by institutions.Read more about Aquestive Therapeutics' insider trading history. Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AQST Stock News HeadlinesAquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells BuyMarch 25, 2025 | seekingalpha.comAquestive Therapeutics: Not For Me, But AttractiveMarch 24, 2025 | seekingalpha.comElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.March 29, 2025 | True Market Insiders (Ad)Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comEarnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their ForecastsMarch 8, 2025 | uk.finance.yahoo.comRaymond James Keeps Their Buy Rating on Aquestive Therapeutics (AQST)March 7, 2025 | markets.businessinsider.comAquestive Therapeutics price target lowered to $7 from $8 at Raymond JamesMarch 7, 2025 | markets.businessinsider.comAquestive Therapeutics Inc (AQST) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...March 7, 2025 | finance.yahoo.comSee More Headlines AQST Stock Analysis - Frequently Asked Questions How have AQST shares performed this year? Aquestive Therapeutics' stock was trading at $3.56 at the beginning of 2025. Since then, AQST stock has decreased by 15.2% and is now trading at $3.02. View the best growth stocks for 2025 here. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its earnings results on Wednesday, March, 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.05. The business earned $11.87 million during the quarter, compared to analysts' expectations of $13.11 million. When did Aquestive Therapeutics IPO? Aquestive Therapeutics (AQST) raised $60 million in an IPO on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. Who are Aquestive Therapeutics' major shareholders? Aquestive Therapeutics' top institutional investors include Vanguard Group Inc. (4.77%), VR Adviser LLC (2.88%), Franklin Resources Inc. (2.34%) and Geode Capital Management LLC (1.81%). Insiders that own company stock include Alexander Mark Schobel, Cassie Jung, Daniel Barber, Peter E Boyd and Lori J Braender. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aquestive Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and General Electric (GE). Company Calendar Last Earnings3/05/2025Today3/29/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AQST CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$10.57 High Stock Price Target$17.00 Low Stock Price Target$7.00 Potential Upside/Downside+250.0%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,870,000.00 Net Margins-59.75% Pretax Margin-59.58% Return on EquityN/A Return on Assets-33.96% Debt Debt-to-Equity RatioN/A Current Ratio6.37 Quick Ratio5.91 Sales & Book Value Annual Sales$57.56 million Price / Sales5.19 Cash FlowN/A Price / Cash FlowN/A Book Value($1.59) per share Price / Book-1.90Miscellaneous Outstanding Shares98,871,000Free Float84,021,000Market Cap$298.59 million OptionableOptionable Beta2.76 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:AQST) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.